Publications by authors named "Matthew A Fuller"

Claim this Profile
P
Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of the US Department of Veterans Affairs and US Department of Defense Clinical Practice Guidelines.
Robert W Buchanan, Ira Katz, Fuad Issa, Rachael Coller, Matthew A Fuller

Schizophr Bull· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Aaron S Wolfgang, Vetisha L McClair, Paula P Schnurr, Paul E Holtzheimer, Josh D Woolley, Matthew A Fuller

Am J Psychiatry· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synopsis of the 2023 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline for the Management of Bipolar Disorder.
Michael J Ostacher, Christopher J Miller, Amanda Edwards-Stewart, Paulette T Cazares, Richard R Owen, Matthew A Fuller

J Clin Psychiatry· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
Paula P Schnurr, Jessica L Hamblen, Jonathan Wolf, Rachael Coller, Claire Collie, Matthew A Fuller

Ann Intern Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
David W Oslin, Kevin G Lynch, Mei-Chiung Shih, Erin P Ingram, Laura O Wray, Matthew A Fuller

JAMA· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Insomnia Associated With Different Formulations of Bupropion.
Kamal Gandotra, George E Jaskiw, Scott G Williams, Matthew A Fuller, Peijun Chen

Prim Care Companion CNS Disord· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophrenia.
Robert J Willborn, Colleen P Hall, Matthew A Fuller

Ment Health Clin· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics.
Chelsea N Carr, Colleen P Hall, Jennifer E Roche-Desilets, Christopher J Burant, Matthew A Fuller

Ment Health Clin· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study to assess subjective and objective reporting of potential adverse drug reactions in older versus younger HIV-infected patients using antiretroviral therapy.
Amy A Hirsch, Anita Compan, Renée H Lawrence, Janet M Briggs, Gopala K Yadavalli, Matthew A Fuller

J Assoc Nurses AIDS Care· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Theodore E Pikoulas, Matthew A Fuller

Ann Pharmacother· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurasidone: an atypical antipsychotic for schizophrenia.
Vineeta Risbood, Jennifer R Lee, Jennifer Roche-Desilets, Matthew A Fuller

Ann Pharmacother· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asenapine: a new antipsychotic option.
Jessica M Henry, Matthew A Fuller

J Pharm Pract· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clozapine: toxicity vs. postmortem redistribution.
George E Jaskiw, P E Konicki, Matthew A Fuller

Schizophr Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical considerations for carbamazepine use in bipolar disorder.
Matthew A Fuller, Victor Dostrow, Sanjay Gupta, Thomas D Gazda

Expert Opin Drug Saf· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risperidone in the treatment of bipolar mania.
Martha Sajatovic, Madhusoodanan Subramoniam, Matthew A Fuller

Neuropsychiatr Dis Treat· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catatonic schizophrenia and the use of memantine.
Stacey S Carpenter, A Daniel Hatchett, Matthew A Fuller

Ann Pharmacother· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessing carbamazepine in the treatment of bipolar disorder: clinical implications of new data.
Hagop S Akiskal, Matthew A Fuller, Robert M A Hirschfeld, Paul E Keck, Terence A Ketter

CNS Spectr· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risperidone for bipolar disorders.
Martha Sajatovic, Subramoniam Madhusoodanan, Matthew A Fuller, Lakynetiew Aulakh, Daniel B Keaton

Expert Rev Neurother· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders.
George E Jaskiw, Per T Thyrum, Matthew A Fuller, Lisa A Arvanitis, Chiao Yeh

Clin Pharmacokinet· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting injectable risperidone.
Megan J Ehret, Matthew A Fuller

Ann Pharmacother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duloxetine: a dual reuptake inhibitor.
Sara E Dugan, Matthew A Fuller

Ann Pharmacother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating clinical monitoring into electronic orders for antipsychotics.
Jennifer Roche-Desilets, Matthew A Fuller, P Eric Konicki

Psychiatr Serv· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Matthew A Fuller, Kenneth M Shermock, Michelle Secic, Amy L Grogg

Pharmacotherapy· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
Matthew A Fuller, Kenneth M Shermock, Michelle Secic, Jonathan S Laich, Michael B Durkin

Psychiatr Serv· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.
Mary C Borovicka, Matthew A Fuller, P Eric Konicki, John C White, Vickie M Steele

J Clin Psychiatry· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis